Funding profile · Computational drug discovery

Macromoltek

Sixteen years old, never a Form D. The only capital that can be audited is $1.37 million of National Science Foundation grant money and a $120,000 Y Combinator check.

$1.37MFederal grants on record, NSF SBIR Phase I and II, 2015 to 2020
$120KY Combinator investment reported at the Winter 2018 batch
92%Share of documented capital that is non-dilutive federal money
0Form D filings on SEC EDGAR since the company was founded

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2010 to 2015 Bootstrapped Not disclosed Founders Founder interview
Jul 1, 2015 NSF SBIR Phase I, award 1520463 $178,700 National Science Foundation Federal record
Jul 9, 2015 Seed, per one database only Not disclosed Capital Factory, per Tracxn Database, unconfirmed
Sep 1, 2016 NSF SBIR Phase II, award 1632399 $1,193,494 National Science Foundation Federal record
Mar 8, 2018 Y Combinator, Winter 2018 batch $120,000 Y Combinator Independent
2018 to 2026 No round disclosed None found None named Nothing found

What the filings show

Macromoltek, Inc. · SEC EDGAR · no filings of any kind

Form D
None
Full text search
0 hits for Macromoltek across all forms, run Sep 23, 2026
Company search
No matching companies
Vehicles
No SPV or fund filing names the company
Caveat
An issuer raising under Section 4(a)(2) rather than Regulation D files no Form D, so absence is not proof that no equity was sold

National Science Foundation · SBIR Phase II · award 1632399

Obligated
$1,193,494
Period
Sep 1, 2016 to Aug 31, 2020
Principal investigator
Monica Berrondo
Title
Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
Record
NSF award database and USAspending

National Science Foundation · SBIR Phase I · award 1520463

Obligated
$178,700
Period
Jul 1, 2015 to Jun 30, 2016
Principal investigator
Monica Berrondo
Title
Automated Humanization of Antibodies Directed to Protein and Carbohydrate Antigens
Record
NSF award database and USAspending

Reading the filings

  1. Nine tenths of the money came from taxpayers.Documented capital is $178,700 plus $1,193,494 plus $120,000, or $1,492,194. The two NSF awards are $1,372,194 of that, about 92 percent. Most companies in this sector show the reverse ratio.
  2. The missing Form D is the finding.Two EDGAR searches on September 23, 2026, one full text and one by company name, returned nothing at all. In sixteen years the company has never filed a Regulation D notice, and no fund or SPV filing names it. A priced venture round is hard to do without leaving that trace.
  3. One database total, and it matches the accelerator check.Tracxn puts lifetime funding at $120,000, the same figure VentureBeat reported for the Y Combinator investment in March 2018. If any later equity had been raised and reported, that total would have moved. The same page lists Capital Factory as a July 2015 investor, which no filing or release confirms.
  4. The customer economics were small.At Y Combinator demo day the company reported $50,000 of revenue for 2017 from ten paying customers, about $5,000 each, plus $500,000 in letters of intent, ten times the realized revenue. Those are project fees, not platform licences, and they explain how a business this old stayed unfunded.
  5. The grant engine switched off in 2020.Phase II ended August 31, 2020. NIH RePORTER shows no project and USAspending shows no federal contract, so nothing replaced it. For a company whose largest backer was the NSF, six years without a federal award is the most concrete negative signal in the record.

Commercial signals

Signal Detail Source type
Revenue $50,000 for 2017 across ten paying customers, reported from Y Combinator demo day Independent
Pipeline $500,000 in letters of intent as of March 2018 Independent
Named customers None, in any year. Partners described only as large biopharmas and smaller biotechs across five countries Company-stated
Partnership Cytovia Therapeutics, April 2020, SARS-CoV-2 arm of a bi-functional NK engager. The stated clinical goal for end of 2020 has no public follow through Timeline unmet
Headcount The 2018 site listed a dozen staff and interns. The current site lists two founders Company pages
Facilities Listed as an alumni company by the ACC Bioscience Incubator, where the bench work was done Independent
Federal NSF Phase II closed Aug 2020. No award, contract or NIH project since Public record

What to watch

  • A first Form D. It would be the first securities filing in the company history.
  • A new SBIR or STTR award, which would restart the only funding line that ever scaled here.
  • A named customer, a licensed molecule, or a design that shows up in a partner pipeline.
  • Whether the two person leadership page is a lean services model or the end of one.

The Macromoltek story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Abalone Bio: Shared investor: Company-Stated Partners. An East Bay biotech that screens antibodies for what they do to a receptor, not how tightly they stick to it
  • Pirouette Pharma: Shared investor: Company-Stated Partners. A disk-shaped, push-button auto-injector built by three engineers who met running a student rocket lab, now paired with old drugs on abbreviated FDA pathways
  • Shiru: Shared investor: Company-Stated Partners. An AI company that mines natural proteins for food functions, then sells the ones that work
  • TAXA Biotechnologies: Shared investor: Company-Stated Partners. The company behind the first synthetic biology crowdfunding campaign

Sources

  1. Public recordSEC EDGAR full text search and company search for Macromoltek, zero resultsSEC · Sep 23, 2026
  2. Public recordNSF SBIR Phase I award 1520463 and Phase II award 1632399NSF and USAspending · 2015 to 2020
  3. Public recordNIH RePORTER project search and USAspending contract search, zero resultsNIH and USAspending · Sep 23, 2026
  4. IndependentMother-daughter duo joins Y Combinator to accelerate drug discovery platform MacromoltekVentureBeat · Mar 8, 2018
  5. IndependentHere are 64 startups that launched today at Y Combinator’s W18 Demo DayTechCrunch · Mar 19, 2018
  6. IndependentMacromoltek funding rounds and investorsTracxn · accessed Sep 23, 2026
  7. InterviewInterview: Rising Star Monica Berrondo from MacromoltekUnder30CEO · May 8, 2013
  8. IndependentCurrent and alumni member companiesACC Bioscience Incubator · accessed Sep 23, 2026
  9. PartnerCytovia Therapeutics and Macromoltek to develop dual-acting natural killer immunotherapy against SARS CoV2GlobeNewswire · Apr 7, 2020
  10. CompanyMacromoltek website and team page, and the 2018 about page archivemacromoltek.com and Internet Archive · accessed Sep 23, 2026

Compiled from SEC, NSF, NIH and USAspending public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; an issuer that raises under another exemption files none, so the absence of a filing is evidence about disclosure rather than proof about capital. Healthcare Venture Capital Fund holds no position in Macromoltek. This page is not an offer to sell or a recommendation to buy any security.